BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy

#	Paper	IF	Citations
10	Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 1937-1942	2.9	1
9	Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia. *Leukemia Research*, **2018**, 72, 59-66	2.7	6
8	The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 370, 25-34	4.7	7
7	Pyrvinium Pamoate Use in a B cell Acute Lymphoblastic Leukemia Model of the Bone Tumor Microenvironment. *Pharmaceutical Research*, **2020**, 37, 43	4.5	7
6	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. *Blood*, **2021**, 137, 812-825	2.2	3
5	Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia. *Oncotarget*, **2017**, 8, 8022-8034	3.3	25
4	Targeting the dysfunctional mitochondrial respiration in drug resistant B-cell acute lymphoblastic leukemia.		
3	The Bone Marrow Microenvironment in B-Cell Development and Malignancy.. *Cancers*, **2022**, 14,	6.6	1
2	Pitavastatin Is Anti-Leukemic in a Bone Marrow Microenvironment Model of B-Lineage Acute Lymphoblastic Leukemia. *Cancers*, **2022**, 14, 2681	6.6	
1	B-cell lymphoma 6 (BCL6): From master regulator of humoral immunity to oncogenic driver in pediatric cancers..		0